MENLO PARK, Calif., Sept. 1, 2015 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the company has submitted its preliminary response to the Patent Trial and Appeals Board (PTAB) in response to two petitions for inter partes review (IPR), filed by a unit of Boston Scientific Corporation, challenging the validity of certain claims in U.S. Patent No. 8,359,102 (the '102 patent). The '102 patent is one of Nevro's 55 issued U.S. patents directed to Nevro's innovations in the neuromodulation field.
The preliminary response is limited in scope by the rules governing the IPR process. The response is limited to setting forth the reasons why an IPR should not be instituted and cannot argue the merits or include any new testimonial evidence.
The company's response may be accessed on the USPTO's website at the following link and entering the patent number 8359102: https://ptabtrials.uspto.gov
By the rules governing the IPR process, the next step will be a decision by the PTAB to either institute or deny review of the petition. That determination is expected by December 1st, 2015.
Headquartered in Menlo Park, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Investor Relations Contact: Westwicke Partners Lynn Pieper (415) 202-5678 email@example.com
SOURCE Nevro Corp.